cSVF Therapy for Frailty Syndrome
(GARM-W Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment to help people with frailty syndrome feel better and improve their daily lives. The process involves taking and concentrating cells from a person's own fat tissue, then reintroducing them into the body through an IV. This method is known as Autologous Stem/Stromal Cellular Stromal Vascular Fraction (cSVF) therapy. The goal is to determine if this can safely boost energy levels and overall health. Suitable candidates for this trial are individuals over 40 who have experienced a decline in energy and exercise ability over the past six months. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could enhance the quality of life for many.
Do I need to stop my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this protocol is safe for humans?
Research has shown that using a person's own cells, called autologous stromal vascular fraction (cSVF), is generally safe. In a study with 421 patients, cSVF combined with platelet-rich plasma was well-tolerated, and most patients did not experience serious side effects.
Another safety review from several clinical sites found that cSVF taken from fat tissue is safe to use. Participants in these studies usually had only mild reactions, if any. However, a potential risk exists when cSVF is administered through an IV, as the cells might get trapped in the lungs, which could be a concern.
Overall, evidence suggests cSVF is mostly safe but does have some risks. Participants should consider these when thinking about joining a trial.12345Why are researchers excited about this trial?
Researchers are excited about the cSVF therapy for frailty syndrome because it uses the body's own stem and stromal cells, which could offer a more natural and potentially less invasive treatment option. Unlike traditional medications or physical therapy, cSVF involves harvesting a small amount of the patient's own fat tissue and isolating the cellular stromal vascular fraction, which is rich in regenerative cells. This approach aims to directly rejuvenate tissues and improve physical function by delivering these cells intravenously. The potential for a personalized treatment that taps into the body's natural healing capabilities sets cSVF apart from existing options.
What evidence suggests that this trial's treatments could be effective for frailty syndrome?
Research has shown that a treatment called autologous stromal vascular fraction (cSVF) might improve the quality of life for people with frailty syndrome. In a study with 421 patients, researchers found that cSVF mixed with platelet-rich plasma (PRP) was safe and showed potential benefits. Participants in this trial will receive cSVF derived from their own fat tissue, which contains cells that may help repair and regenerate tissues. Early research suggests these cells could slow down or even reverse some effects of aging. While more research is needed, these findings offer hope for improving health and function in older adults.12367
Who Is on the Research Team?
Michael Nissenbaum, MD
Principal Investigator
Healeon Medical
Are You a Good Fit for This Trial?
This trial is for people aged 40-90 who feel weaker and less able to exercise over the last six months, can walk a certain distance in six minutes, and are willing to consent. It's not for those with uncontrolled high blood pressure, recent drug or alcohol abuse, very short life expectancy, severe neurodegenerative diseases that affect walking tests, poor mental function scores on MMSE, certain cancers within 2 years (except some skin lesions), abnormal blood values or serious co-morbidities.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Lipoaspiration
Closed microcannula harvesting of small volume of subdermal adipose tissue, including the stromal cellular and stromal tissue using sterile, disposable, microcannula system
Isolation & Concentration of cSVF
Isolation and Concentration of cellular stromal vascular fraction (cSVF) using a Healeon Medical CentriCyte 1000 centrifuge, incubator and shaker plate with sterile Liberase enzyme
Treatment
Delivery of cSVF via intravenous infusion with 500cc Normal Saline over 30-60 minutes
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Autologous Stem/Stromal Cellular Stromal Vascular Fraction (cSVF)
Trial Overview
The trial is testing if injecting patients' own processed fat tissue cells back into their bloodstream can improve quality of life and health in aging. Fat tissue is taken from the patient's body using a special technique called Microcannula harvest adipose stromal tissues. The cells are then isolated with an enzyme digestion system before being returned via IV.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Closed microcannula harvesting of small volume of subdermal adipose tissue, including the stromal cellular and stromal tissue using sterile, disposable, microcannula system
Isolation and Concentration of cellular stromal vascular fraction (cSVF) using a Healeon Medical CentriCyte 1000 centrifuge, incubator and shaker plate with sterile Liberase enzyme (Roche Medical) per manufacturer protocols
cSVF from Arm 2 is suspended in a 500cc of sterile Normal Saline and deployed through 150 micron in-line filtration and intravenous route over 30-60 minute time frame.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Healeon Medical Inc
Lead Sponsor
Micheal Nissenbaum, MD
Collaborator
Terry, Glenn C., M.D.
Collaborator
Published Research Related to This Trial
Citations
Study Details | NCT03514537 | Autologous Stem/Stromal ...
The intent of this trial is to determine the safety and efficacy of delivery of autologous cellular stromal vascular fraction (cSVF) to improve the quality of ...
2.
ctv.veeva.com
ctv.veeva.com/study/autologous-stem-stromal-cellular-stromal-vascular-fraction-csvf-in-frailty-aging-processesAutologous Stem/Stromal Cellular Stromal Vascular Fraction ...
The intent of this trial is to determine the safety and efficacy of delivery of autologous cellular stromal vascular fraction (cSVF) to improve ...
cSVF Therapy for Frailty Syndrome (GARM-W Trial)
In a study involving 421 patients, the administration of autologous stromal vascular fraction (SVF) mixed with platelet-rich plasma (PRP) was found to be safe, ...
Autologous Stem/Stromal Cellular Stromal Vascular
The intent of this trial is to determine the safety and efficacy of delivery of autologous cellular stromal vascular fraction (cSVF) to improve the quality of ...
Recent clinical trials with stem cells to slow or reverse ...
Several clinical trials have been launched in order to evaluate the efficacy of mesenchymal stem cell interventions to slow or reverse normal aging processes.
Safety Analysis of Autologous Stem Cell Therapy in a ...
In this study, we report a safety analysis of multiple clinical sites utilizing stromal vascular fraction (SVF) derived from the fat tissue for ...
Recent clinical trials with stem cells to slow or reverse ...
However, intravenous administration runs the risk of entrapment of the stem cells in the lungs (and could raise safety concerns). In addition to ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.